Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysis

BACKGROUND: Curbing or reversing high glycated hemoglobin (HbA1c) and body mass index (BMI) are two essential parts in the clinical management of type 2 diabetes (T2D). We delineated the changing patterns of the baseline HbA1c and BMI in patients with T2D from placebo-controlled randomised trials to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Suiyuan, Lin, Chu, Cai, Xiaoling, Li, Zonglin, Lv, Fang, Yang, Wenjia, Ji, Linong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971277/
https://www.ncbi.nlm.nih.gov/pubmed/36864984
http://dx.doi.org/10.1016/j.eclinm.2023.101868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971277/
https://www.ncbi.nlm.nih.gov/pubmed/36864984
http://dx.doi.org/10.1016/j.eclinm.2023.101868

Ejemplares similares